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Background: Molecular studies have tried to address the unmet need for prognostic biomarkers 
in prostate cancer (PCa). Some gene expression tests improve upon clinical factors for 
prediction of outcomes, but additional tools for accurate prediction of tumor aggressiveness 
are needed.  
Methods: Based on a previously published panel of 23 gene transcripts that distinguished 
patients with metastatic progression, we constructed a prediction model using independent 
training and testing datasets. Using the validated mRNAs and Gleason score (GS), we performed 
model selection in the training set to define a final locked model to classify patients who 
developed metastatic-lethal events from those who remained recurrence-free. In an 
independent testing dataset, we compared our locked model to established clinical prognostic 
factors and utilized Kaplan-Meier curves and ROC analyses to evaluate the model’s 
performance.  
Results: Thirteen of 23 previously identified gene transcripts that stratified patients with 
aggressive PCa were validated in the training dataset. These biomarkers plus GS were used to 
develop a four-gene (CST2, FBLN1, TNFRSF19, ZNF704) transcript (4GT) score that was 
significantly higher in patients who progressed to metastatic-lethal events compared to those 
without recurrence in the testing dataset (p-value = 5.7x10-11). The 4GT score provided higher 
prediction accuracy (AUC = 0.76, 95% CI: 0.69-0.83; pAUC = 0.008) than GS alone (AUC = 0.63, 
95% CI: 0.56-0.70; pAUC = 0.002), and it improved risk stratification in subgroups defined by a 
combination of clinicopathological features (i.e., CAPRA-S). 
Conclusions: Our validated 4GT score has prognostic value for metastatic-lethal progression in 




Second to lung cancer, prostate cancer (PCa) is the most common cause of cancer-related 
mortality in American men. In 2019 there will be 174,650 new cases and 31,620 deaths from 
the disease.1 PCa is clinically and biologically heterogeneous. Among patients diagnosed with 
localized tumors who undergo radical prostatectomy (RP), about 30-40% will have adverse 
clinicopathologic features such as a high Gleason score (GS), positive surgical margins, seminal 
vesicle involvement, extra capsular extension or a high PSA level that increase risk of metastatic 
progression.2-4 While only a subset of these men will develop metastatic, life-threatening PCa,5,6 
many of these patients will receive secondary therapy such as postoperative radiation and may 
suffer from treatment-related morbidity. On the other hand, some men without higher risk 
clinicopathologic features at diagnosis will develop biochemical recurrence (BCR), metastasis 
and die of PCa. Current clinicopathological factors have limitations in terms of predicting which 
men are at high risk for metastasis and cancer-related death. Prognostic biomarkers that can 
accurately predict risk of metastatic-lethal progression are needed to advance personalized 
medicine. 
Over the last decade, molecular studies have tried to address the unmet clinical need for 
better prognostic biomarkers. Tumor-derived gene expression signatures may have added value 
to clinical factors for correctly stratifying patients with aggressive PCa,7,8 and three 
commercially available RNA-based tests have been externally validated.9-16 However, there is 
room to improve upon these molecular tests by identifying other biomarkers associated with 
tumor metastatic potential. 
Recently, Rubicz et al. identified and validated a panel of 23 prognostic gene transcripts 
from transcriptome data measured in primary tumors.17 To further investigate the potential 
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clinical utility of these 23 mRNA biomarkers, we evaluated their prognostic performance in a 
retrospective, nested case-control study dataset.18 We then developed a prognostic four-gene 
transcript (4GT) score to improve upon GS for predicting metastatic-lethal events. The 4GT 
score was then validated in a second independent testing dataset.  
Materials and Methods 
 
Training dataset 
To further evaluate the panel of 23 prognostic mRNAs, we used data from PCa patients 
identified through the Mayo Clinic (MC) RP Tumor Registry using a nested case-control design 
as described previously.18 In brief, patients that received RP between 1987 and 2001 were 
retrospectively classified into outcome groups: 1) no evidence of disease (NED) at ≥7 years of 
follow-up (n = 213); 2) biochemical recurrence (BCR), defined as two successive PSAs >0.20 
ng/ml and no detectable metastasis within 5 years of BCR (n = 213); and, 3) early metastasis 
defined by a positive bone or CT scan within 5 years after BCR (n = 213). Each metastatic case 
was matched by birth year, calendar year of PSA increase, and diagnostic Gleason score, to a 
patient from both the NED and the BCR groups.18  Tumor gene expression data were available 
from 169 NED patients, 184 BCR patients and 192 metastatic patients.  
In comparison to the original study,18 we defined the cases differently and combined all 
patients who developed metastasis or died of PCa into a metastatic-lethal category, including 
20 patients who were classified as BCR in the original study but who developed metastasis 
during further follow-up. This metastatic-lethal group (n = 212) was compared to NED patients 
(n = 157) in these analyses. The Affymetrix HuEx 1.0ST array and Single Channel Array 





We used an independent study population from the MC Tumor Registry as the testing dataset 
for validation. This case-cohort study initially sampled 1,010 RP patients treated between 2000 
and 2006, and who were at high risk for recurrence based on a preoperative PSA >20 ng/ml, 
pathological GS ≥8, seminal vesicle involvement or a MC nomogram score of ≥10.10 A random 
sample of 202 men, together with all remaining men with metastatic progression were drawn 
from the cohort, resulting in a dataset of 256 men. We combined patients who developed 
metastasis or died of PCa into a metastatic-lethal category and compared them to patients with 
NED. The final MC testing dataset included 110 non-recurrent and 76 metastatic-lethal cases. 
Statistical Analysis 
To evaluate the panel of 23 gene transcripts in the MC training dataset, we calculated the 
difference between mean expression of each transcript in the non-recurrence and metastatic-
lethal groups. For each transcript, we also examined the p-value for the area under the ROC 
curve (AUC) and the partial area under the ROC curve (pAUC) at 95% specificity using 
permutation tests, compared to a totally random prediction model. A transcript was considered 
validated if its expression level between patient groups in the MC training dataset was in the 
same direction (lower or higher) as that in the earlier study,17 and if the p-value for the AUC, 
pAUC or the two-sided t-test was significant (p-value <0.05).  
We next evaluated the performance of each transcript that validated in the MC training 
data for its ability to classify men with metastatic-lethal outcomes in combination with GS, 
which was coded as continuous (i.e., 1: GS ≤6; 2: GS = 7; and, 3: GS ≥ 8). For each validated 
transcript, we compared the AUC and pAUC from a model of the mRNA combined with GS to a 
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model with GS alone. Likelihood ratio tests were used to compare the goodness of fit for base 
models with GS alone and alternative models fit with GS and an additional transcript.  
We next performed stepwise (forward) logistic regression starting with GS in the model 
using the MC training dataset. At each step, a mRNA was added to the model one at a time and 
a likelihood ratio test was performed to compare a model including a single additional 
transcript with the model from the previous step. The transcript with the lowest p-value was 
added at each step until all remaining transcripts had a p-value >0.05. The coefficients from the 
final locked model in the training dataset were then used to calculate a gene transcript score by 
multiplying with the corresponding mRNA levels and the GS for each patient in the MC testing 
dataset. Importantly, the testing dataset was not evaluated until after the model from the 
training set was locked. 
A receiver operating characteristic (ROC) analysis and discrimination boxplots of non-
recurrent vs. metastatic-lethal patients were performed to evaluate the ability of the gene 
transcript score to distinguish patient groups. The AUC and pAUC were computed for the final 
model, as well as for GS alone and for the Cancer of the Prostate Risk Assessment-Surgery 
(CAPRA-S) score.19 We then dichotomized patients in the testing dataset into low and high gene 
transcript score groups at zero, which represents the median score. Kaplan-Meier analysis was 
conducted to compare metastatic-free survival between the low and high gene transcript score 
groups. The p-value for the log-rank test was used to evaluate the significance of the group 
difference in the score. 
We also examined the performance ability of the gene transcript score in patients stratified 
by CAPRA-S score. Patients with a CAPRA-S score ≤5 were categorized as low-medium risk and 
patients with a CAPRA-S score ≥6 were categorized as high risk. Boxplots and a t-test between 
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Selected characteristics of the MC training and testing datasets are listed in Table I. For both 
datasets, the mean age at diagnosis of patients with metastatic-lethal events was similar to that 
of patients with no recurrence. As expected, men with adverse outcomes were more likely to 
have a higher CAPRA-S score, a higher GS, regional stage disease, and higher PSA levels at 
diagnosis. 
We first examined the 23 biomarkers in the training dataset, where transcripts from 13 
genes (ALDH1A2, CENPE, CST2, DPT, FBLN1, PI15, PLCL2, SELE, SPRY4, SRD5A2, TNFRSF19, TPX2, 
ZNF704) had the same direction of expression as in the original study 17 and had a significant p-
value (<0.05) for the two-sided t-test, AUC test or the pAUC test (Table II). In this training 
dataset, we next evaluated the ability of the 13 validated mRNAs to improve upon GS for 
differentiating men with adverse events (Supplemental Table I). The AUC for GS alone in the MC 
training dataset was 0.72, and addition of each transcript to a model with GS improved all the 
AUCs (range: 0.73 to 0.76). Likelihood ratio tests for differential expression between the two 
patient groups were significant (p-value <0.05) for 11 mRNAs. The forward stepwise logistic 
regression model based on GS and the most robust of the 13 transcripts led to a final locked 
model that included four transcripts (CST2, FBLN1, TNFRSF19, ZNF704).  
The coefficients from this final locked model (Table III) were then applied to the testing 
dataset to calculate a four-gene transcript (4GT) score, which ranged from -4.09 to 5.55 
(recurrence-free: range -4.09 to 5.55; metastatic-lethal: range -0.82 to 4.45). The mean 4GT 
score differed significantly between patient groups (Figure 1A: mean difference = 1.44; p-value 
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= 5.7x10-11). Based on the logistic regression analysis, each unit increase in the 4GT score was 
associated with a significantly elevated odds ratio of 2.05 (95% CI = 1.60 - 2.70; p-value = 
6.4x10-8). Stratifying by CAPRA-S score, the 4GT score in the low-medium risk group had a mean 
of -0.37, and in the high-risk group the mean was 1.26 (Figure 1B: mean difference = 1.63; p-
value = 2.3x10-13). 
We next evaluated time to metastasis in the low and high 4GT score groups (dichotomized 
at a score of 0) using Kaplan-Meier analysis (Figure 2). Median follow-up time of all patients was 
5.1 years. Twelve of 72 (16.7%) patients in the low 4GT score group developed metastases 
whereas 64 of 114 (56.1%) patients in the high 4GT score group had metastatic progression. 
The overall metastasis-free survival was significantly different between the groups (p-value = 
3.7×10-7).  
In the testing dataset, a ROC curve analysis (Figure 3A) confirmed that the 4GT score had 
better predictive performance (AUC = 0.76, 95% CI = 0.69 – 0.83; 95% pAUC = 0.008) than GS 
alone (AUC = 0.63, 95% CI = 0.56 – 0.70; pAUC = 0.002) or the CAPRA-S score (AUC = 0.75, 95% 
CI = 0.68 – 0.82; 95% pAUC = 0.005). The AUC for the 4GT score model was significantly higher 
than the AUC for the GS alone model (p-value <0.001), but not the CAPRA-S alone model (p-
value = 0.9). Addition of the 4GT score to a model that included CAPRA-S score increased the 
AUC to 0.77 (95% CI = 0.70 – 0.83).  
The pAUC (at 95% specificity) for our model (0.008) in the testing dataset was higher 
compared to Gleason alone (pAUC = 0.002) or CAPRA-S alone (pAUC = 0.005). This indicates 
that the 4GT score has a higher probability of correctly classifying men at high risk for 
metastatic progression, while maintaining a high probability of correctly classifying truly low-
risk patients.  
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To further assess the performance and clinical utility of the 4GT we next stratified the 
testing dataset by CAPRA-S score, which uses available clinicopathological data from RP to 
define prognostic risk groups (e.g., low-medium vs. high). Results from these analyses indicate 
that the 4GT score can improve upon CAPRA-S for more accurate classification of patients 
within risk strata. For men with low-medium CAPRA-S scores (Figure 3B; 96 patients), the 4GT 
score (AUC = 0.74, 95% CI = 0.64 – 0.84; pAUC = 0.008) outperformed GS (AUC = 0.67, 95% CI = 
0.56 – 0.78; pAUC = 0.003). Of the 96 patients in the low-medium risk group, CAPRA-S 
misclassified 22 (23%) who had metastatic progression, and the majority of these (64%) were 
correctly classified as high-risk by the 4GT score. In patients with high CAPRA-S scores (Figure 
3C; 88 patients), the 4GT score performed much better (AUC = 0.64, 95% CI = 0.52 – 0.76; pAUC 
= 0.004) than GS alone (AUC = 0.45, 95% CI = 0.35 – 0.55; pAUC = 0.001). Of these 88 patients, 
35 (40%) remained recurrence-free and may have been misclassified as high-risk by the CAPRA-
S score; the 4GT score correctly classified (26%) of these patients as low-risk.  
Discussion 
In this study, we evaluated a panel of 23 gene transcripts previously validated to predict 
metastatic-lethal events in men treated for localized PCa,17 and constructed a prediction model 
in a training dataset based on GS and validated transcripts from four genes (CST2, FBLN1, 
TNFRSF19, ZNF704). We tested our prediction model on an independent validation dataset in 
which the 4GT score stratified patients by outcome (recurrence-free vs. metastatic-lethal, p-
value = 5.7x10-11) and demonstrated an AUC = 0.76 (95% CI: 0.69 – 0.83) and a pAUC = 0.008 (at 
95% specificity) for prediction of metastatic-lethal progression. The 4GT score provided 
additional prognostic information within CAPRA-S defined risk strata (i.e., low-medium or high), 
allowing for more accurate classification of patients. 
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Our work builds on the three gene expression tests currently available in clinical practice. 
The Prolaris test measures 46 transcripts, was found to predict BCR after RP,20 and can stratify 
patients at low risk (i.e., CAPRA-S score ≤2). The test improved prediction accuracy of the 
CAPRA-S score, which increased from a c-index of 0.73 to 0.77 with the addition of the Polaris 
panel. The 17 mRNAs in the Oncotype DX test were identified using tumor tissue from low-
intermediate risk patients.14 The test was an independent predictor of BCR (HR = 2.7), 
metastases (HR = 3.8) and adverse pathology (OR = 3.3) in low-intermediate risk patients.16 The 
AUC for the Oncotype DX genomic score (AUC = 0.68) improved when it was combined with the 
CAPRA-S score (AUC = 0.73). The Decipher test 9 includes 22 gene transcripts, was developed 
using a case-control dataset, and was designed to predict metastasis after a rising PSA (AUC = 
0.75). Cooperberg et al. 11 found that the Decipher test combined with the CAPRA-S score 
predicted PCa mortality in high-risk men (c-index = 0.78), all of whom had adverse pathology 
documented at radical prostatectomy. In the MC population that we used as a testing dataset, 
the Decipher test was previously applied to predict early metastasis (i.e., within 5 years after 
RP), and outperformed clinical models with an AUC of 0.79.10 Because these tests were 
developed using different populations and methodologies, with heterogeneity in the 
clinicopathologic characteristics of patients and outcomes evaluated, it is difficult to directly 
compare results across studies.  
Compared to the tests described above, the 4GT score demonstrated similar or slightly 
better prognostic performance for distinguishing low-risk vs. high-risk patients for subsequent 
metastatic-lethal events. Furthermore, the 4GT score may offer some advantages over the 
other tests. Given that it is based on expression levels of only four mRNAs, the 4GT test is 
straightforward to calculate and should be less expensive to perform than current tests that 
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cost $3,400 to $4,180. A low-cost prognostic biomarker test could become more widely used as 
a clinical tool for patient management, especially among patients with limited or no health 
insurance and in developing countries where PCa diagnoses are predicted to rise. In addition, 
future work based on prostate biopsy samples may provide further support for molecular tests 
such as the 4GT score that measure a limited number of biomarkers given the limited quantity 
of tumor tissue available from needle biopsy specimens. A biopsy-based prognostic test to risk 
stratify patients prior to treatment could potentially guide therapy and improve patient 
outcomes. Lastly, in terms of clinical utility, the 4GT score in the testing dataset was shown to 
have added value to the standard clinicopathologic factors available for RP patients used to 
calculate the CAPRA-S score, providing more accurate classification of patients in both the low-
medium risk and the high-risk CAPRA-S subgroups. 
The four genes represented in the 4GT score have previously been associated with 
biological processes involved in prostate or other cancers. Notably, the tumor necrosis factor 
receptor superfamily member 19 (TNFRSF19) transcript is also included in the Decipher test.9 In 
a study of gastric cancer TNFRSF19 was down-regulated in tumor compared to adjacent benign 
tissue and lower expression levels were associated with worse outcomes.21 This is consistent 
with our finding of lower gene expression levels in men with metastatic progression.  
The basement membrane component fibulin 1 (FBLN1) is suggested to function both as a 
tumor suppressor and an oncogene. Its role as a tumor suppressor is supported by the fact that 
FBLN1 was shown to inhibit migration and invasion.22 Downregulation of FBLN1 in bladder 
cancer was associated with high-grade cancer and lower recurrence-free survival;23 FBLN1 has 
also been observed to be down-regulated in tumors compared to benign prostate tissue,24 
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particularly in tumors with  overexpression of ERG.25 These observations are supported by our 
results where lower FBLN1 expression was associated with metastatic-lethal events.  
Salivary cystatin family member 2 (CST2) was first suggested to be involved in cancer based 
its higher expression in breast cancer compared to normal tissues.26 More relevant to our 
findings are two recent studies that identified nine-gene prognostic signatures for gastric 
cancer, with CST2 present in both. 27,28 We found increased CST2 expression in patients at high 
risk of metastatic-lethal progression.  
Little is known about zinc-finger protein 704 (ZNF704), although one study suggested that it 
plays a role in malignant transformation.29 Data from The Cancer Genome Atlas showed lower 
expression in tumors compared to benign prostate samples, but we found higher ZNF704 
expression in patients with metastatic progression. Further work will be needed to understand 
the role this gene may play in aggressive PCa. 
In summary, we have used independent training and testing datasets to develop and 
validate a 4GT score that is predictive of metastatic-lethal progression in men treated for 
localized PCa. The 4GT score demonstrated added value for improving prognostic classification 
of patients defined as low-medium risk or high-risk CAPRA-S scores. The four mRNAs in this 
score have biological plausibility as prognostic biomarkers and are complimentary to GS for 
predicting adverse events. Based on these results, the 4GT score warrants further evaluation as 
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Figure 1. Box plots of the four-gene transcript (4GT) score in the MC testing dataset stratified by: A) 
prostate cancer outcome status (no recurrence vs. metastatic-lethal progression); and B) CAPRA-S score 
category (low-medium risk vs. high risk group) 
 
Figure 2. Kaplan-Meier estimates for metastatic-free survival in the MC testing dataset stratified by the 
four-gene transcript (4GT) score (low vs. high).  
 
Figure 3. A) Receiver Operating Characteristic curves (ROCs) for predicting metastatic-lethal vs. non-
recurrent prostate cancer outcomes in the MC testing dataset The red line shows the prediction 
performance of Gleason score alone (AUC= 0.63; pAUC= 0.002), the green line shows the prediction 
performance of CAPRA-S score alone (AUC= 0.75; pAUC= 0.005), and the blue line shows the prediction 
performance of the four gene transcript (4GT) score based on Gleason score plus four validated 
transcripts (AUC= 0.76; pAUC= 0.008). B) ROCs for predicting metastatic-lethal vs. non-recurrent 
prostate cancer outcomes in the subset of low-medium CAPRA-S scores (96 patients): The red line shows 
the prediction performance of Gleason score alone (AUC= 0.67; pAUC= 0.003), and the blue line shows 
the prediction performance of the four gene transcript (4GT) score based on Gleason score plus four 
validated transcripts (AUC= 0.74; pAUC= 0.008). C) ROCs for predicting metastatic-lethal vs. non-
recurrent prostate cancer outcomes in the subset of high CAPRA-S scores (88 patients): The red line 
shows the prediction performance of Gleason score alone (AUC= 0.45; pAUC= 0.001), and the blue line 
shows the prediction performance of the four gene transcript (4GT) score based on Gleason score plus 
four validated transcripts (AUC= 0.64; pAUC= 0.004). 
 
 
